Join
Live feed
·
PRReleasevia Quantisnow
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

ByQuantisnow·Wall Street's wire, on your screen.
RARE· Ultragenyx Pharmaceutical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RARE (Ultragenyx Pharmaceutical Inc.) and more on Quantisnow.